Resources

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 9 of this Exclusive Interview, Dr. Mechanick reiterates his call for the individualization of diabetes care.

In this week's Homerun Slides, the baseline characteristics of the randomized, placebo-controlled cardiovascular outcome trial of empagliflozin.

Potential mechanisms of incretin dysfunction in type 2 diabetes: Various potential explanations have been expounded in order to explain the reduced incretin effect in type 2 diabetes. One obvious factor to examine was the secretion of GIP and GLP-1. Regarding GIP, a number of studies have compared postprandial plasma concentrations between patients with and without diabetes. These studies have revealed increased, normal, or reduced GIP levels in patients with diabetes. Considering all studies together, there does not appear to be a general defect in GIP secretion. If anything, a slight increase in postprandial GIP levels might occur in patients with early type 2 diabetes, but clearly the differences in GIP levels would not sufficiently explain any alterations in insulin of glucose concentrations.

To view this video in full, click here. Steve Freed: Maybe start off by telling us a little bit about yourself because you have an interesting background. Dr. Mechanick: I’m a clinical endocrinologist in private practice in New York City and an attending and clinical professor at Mount Sinai, at the Icon …

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting about the role of nutrition and lifestyle as a preventative method in treating diabetes. Dr. Jeffrey Mechanick, MD, FACP, FACE, FNLA is the Clinical Professor of Medicine and Director of Metabolic Support in the …

Which of these Diabetes in Control features are you most likely to read/use? 1. Exclusive interviews 2. Textbook excerpts 3. New products 4. New mobile apps 5. Clinical presentations 6. I read/use them all Follow the link to share your response!

What types of Diabetes in Control content do you find most valuable? 1. Information about new studies and treatments 2. Expert opinions/insights (interviews or guest articles) 3. News from conferences (ADA, AACE, etc.) 4. Case studies/personal accounts (for example, Disasters Averted) 5. Other Follow the link to share your response.

Female, 20 years of age, type 2 diabetes, is obese with anxiety disorder, untoward response to several classes of agents. Reports eating lower carbs since last seen. During the warm weather, random glucose levels and A1C were near normal. Today is a cold winter day. Random glucose 188mg/dl.

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 8 of this Exclusive Interview, Dr. Mechanick explains the comprehensive focus of the AACE A1C guidelines.

In this week's Homerun Slides, EMPA-REG Outcome, examining the long-term effects of empagliflozin versus using a placebo on the heart and mortality risk in patients with type 2.